Nurix Therapeutics has enrolled the first patient in a Phase 1b/2 CLL trial of oral BTK degrader bexobrutideg with Roche, marking an early clinical milestone. The company recently also disclosed $7 million from Pfizer and a $10 million Gilead extension fee.
published
Nurix Therapeutics has enrolled the first patient in a Phase 1b/2 CLL trial of oral BTK degrader bexobrutideg with Roche, marking an early clinical milestone. The company recently also disclosed $7 million from Pfizer and a $10 million Gilead extension fee.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.